TITLE

Reducing Readmissions for Congestive Heart Failure

PUB. DATE
April 2001
SOURCE
American Family Physician;4/15/2001, Vol. 63 Issue 8, p1593
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Hospital admission for congestive heart failure is extremely common and quite expensive, although it is frequently preventable. New drugs and therapies have been reported to reduce admissions, decrease morbidity and mortality, and improve the quality of life for these patients. Patients with an ejection fraction less than 40 percent (decreased systolic function) should be treated with medication to improve symptoms and prevent progression of heart failure. Angiotensin-converting enzyme (ACE) inhibitors are a mainstay of treatment in patients who can tolerate them; in patients who cannot take these drugs, angiotensin II receptor blocking agents offer an alternative. Patients with New York Heart Association class II or III heart failure should also receive a beta blocker (metoprolol, carvedilol or bisoprolol). Recent research has shown that treatment with spironolactone improves mortality and hospital readmission rates. An exercise program should also be recommended for all patients with heart failure unless their condition is unstable.
ACCESSION #
4366394

 

Related Articles

  • People with congestive heart failure...  // Consumers' Research Magazine;Mar1994, Vol. 77 Issue 3, p41 

    Focuses on an article in the `Wall Street Journal,' which suggests that people with congestive heart failure might receive more effective treatment from specialists than from general practitioners. Studies of ACE-inhibitors and the percentage of heart-failure patients who receive these drugs.

  • Older heart drug cuts death rate by 30%. Hensley, Scott // Modern Healthcare;07/26/99, Vol. 29 Issue 30, p24 

    Discusses the re-discovery of spironolactone, a drug that blocks the action of a hormone called aldosterone. Implications of the discovery of the drug on hospitals and health systems; Number of people hospitalized with congestive heart failure.

  • Coronary Stent Implantation in Patients with a Single Coronary Artery. Sasao, Hisataka; Hasegawa, Tohru; Endo, Akita; Fujiwara, Tadashi; Kikuchi, Yuka; Oimatsu, Hiroshi; Takada, Takehito // Angiology;Jan2003, Vol. 54 Issue 1, p131 

    An isolated single coronary artery is a rare congenital anomaly and a cause of cardiac ischemia, congestive heart failure, and sudden cardiac death. Reported here are 3 cases of single coronary artery with acute myocardial infarction in which coronary stenting was performed. Also reported are...

  • Therapeutic options for congestive heart failure. Ross, Brendan S.; King, Jeffery M.; Fischer, Richard G. // Drug Topics;2/16/98, Vol. 124 Issue 4, p102 

    Presents information on congestive heart failure (CHF) with reference to its therapeutic options in the United States. Estimation of the amount of Americans who are afflicted with CHF; What have been associated with the increase prevalence and incidence of heart failure; Details on the diagnosis...

  • New Test for Congestive Heart Failure.  // Medical Update;Jul2002, Vol. 28 Issue 1, p5 

    Provides information on a 15-minute test which detects the presence of congestive heart failure.

  • Medication Safety and Reliability.  // Formulary;Jul2003, Vol. 38 Issue 7, p411 

    Reports on the risk of myocardial damage associated with the prescription and use of cytotoxic agent, doxorubicin, in the field of oncology. Major risk factor for doxorubicin-related congestive heart failure; Results of lung and breast cancer trials; Relation of patient symptoms to doxorubicin.

  • Quality watch. Montague, Jim; Pitman, Hilarie // H&HN: Hospitals & Health Networks;2/5/96, Vol. 70 Issue 3, p14 

    Reports on the benefits of extensive patient education and follow-up care to treat congestive heart failure. Comparison of costs; Implications.

  • ...-blockade saves lives in congestive heart failure. Pinkowish, Mary Desmond // Patient Care;10/15/1997, Vol. 31 Issue 16, p171 

    Reports that according to a meta-analysis, ...-blockade may offer significant mortality reductions to patients with chronic congestive heart failure (CHF). Description of experiments conducted in study; Odds of death; Speculations on the influence of ...-blockers delay on CHF.

  • Old drug, new treatment for severe CHF.  // Brown University Long-Term Care Quality Advisor;Oct99, Vol. 11 Issue 10, p1 

    Reports that generic drug spironolactone has proved to be effective in treating life-threatening congestive heart failure, reducing the death rate by 30 percent. INSET: Aging heads need social support too.

  • Evaluation of treatment for congestive heart failure in patients aged 60 years and older using... Jenkinson, Crispin; Jenkinson, Damian // Age & Ageing;Jan1997, Vol. 26 Issue 1, p7 

    Evaluates treatment for congestive heart failure of older patients using generic measures of health status measures. Form 36 (SF-36) and Dartmouth COOP charts; Angiotensin converting enzyme inhibitor treatment; Indication for SF-36 and COOP charts health status measures; Standardized...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics